In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. July 27, 2018. Opher Shapira.

Executive Summary

Israeli cancer diagnostics firm Nucleix is planning to scale up European commercial activities to expand the reach of its first product for bladder cancer, Bladder EpiCheck. See what Nucleix CEO Opher Shapira said about it here.

"The company is currently in advanced negotiations with additional leading distributors in various European countries to expand its commercial reach. We believe Bladder EpiCheck shows the best performance of bladder cancer recurrence detection compared to all other noninvasive solutions. In addition, the test is easy to adopt in any lab and is highly cost-effective." –Opher Shapira, CEO, Nucleix

Click here for a free trial of Medtech Insight

Related Content

Topics

UsernamePublicRestriction

Register

MT123038

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel